Showing 51–75 of 148 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Andrew D Kerkhoff, Jason Zucker, Diane V Havlir
…pportunistic Infections (CROI) featured numerous studies on tuberculosis and other opportunistic infections in people with HIV. High mortality rate among people with HIV hospitalized with disseminated tuberculosis (TB) and among those treated for drug-resistant TB represents a ma…
Divya Nasare, Shashikant Bagade
Pulmonary tuberculosis (TB), caused by the Mycobacterium tuberculosis (MTB) bacterium, remains a significant health problem worldwide, intensified by the emergence of multidrug-resistant (MDR) and highly resistant (XDR) strains. The current treatment protocols, related side effec…
Sandeep Rai, Abhishek Sen, Harsh Shah, Jay Patel
The emergence of drug-resistant tuberculosis (DR-TB), especially multi drug resistant tuberculosis (MDR-TB), is increasingly threatening the effectiveness of India's National TB Elimination Program (NTEP). This review seeks to analyse the patient and health system challenges conc…
Anna Starshinova, Adilya Sabirova, Igor Kudryavtsev, Artem Rubinstein, Arthur Aquino, et al.
Latent tuberculosis infection (LTBI) represents a biologically active yet clinically asymptomatic stage of(Mtb) persistence. This condition is characterized by subtle immunometabolic alterations reflecting the host-pathogen equilibrium. Understanding the mechanisms and biomarkers…
Yan Zhang, Dian Yuan, Hua-Li Wang, Chao-Qiong Zhou, Yan-Qun Liu, et al.
Tuberculosis (TB) remains a major global public health challenge, and its control efforts are increasingly complicated by the rising prevalence of drug-resistant TB (DR-TB). Rifampicin (RIF), a cornerstone of first-line anti-TB treatment regimens, plays a pivotal role in TB thera…
Binh Nguyen, Greg J. Fox, Paul H. Mason, Justin T. Denholm
Abstract Multidrug resistant tuberculosis (MDR-TB) has a substantial impact on individuals and communities globally, including lengthy, expensive and burdensome therapy with high rates of treatment failure and death. Strategies to prevent disease are well established for those wh…
Chiara Sepulcri, Francesca Saluzzo, Daniele Roberto Giacobbe, Antonio Di Biagio, Daniela Maria Cirillo, et al.
**INTRODUCTION:** Drug-resistant tuberculosis (DR-TB) still represents a critical global health threat despite recent therapeutic advances. The shift from long, injectable-based regimens to shorter, all-oral regimens has improved outcomes, yet substantial challenges remain in ens…
Simon Tiberi, Temi Lampejo, Alimuddin Zumla
Rifampicin-resistant Tuberculosis (RR-TB) and Multidrug resistant Tuberculosis (MDR-TB) are a current global health threat, and are characterised by high mortality, chronic sequelae, complexity and high cost. The drug resistant form of this infectious disease was globally respons…
Nora Engel
…ween standardization and localization in efforts to control tuberculosis (TB); between programmatic considerations and responding to individual care needs, including particular TB strains, co-morbidities, personal pharmaceutical histories or socio-economic circumstances. Drawing …
Rajender Kumar, Apurva Sood, Harmandeep Singh, Bhagwant Rai Mittal
Amongst, extrapulmonary tuberculosis, the abdominal involvement is an important type that may present with nonspecific clinical features. It is considered a mimicker of many other gastrointestinal pathologies; hence it poses a significant diagnostic challenge leading to delayed d…
Nicole Rose Alberto, Isabelle Rose I Alberto, Ianne Keziah Agripo, Gabrielle P Flores, Madeleine Nicole G Bernardo, et al.
Drug-resistant tuberculosis (DR-TB) heavily contributes to the global challenge of antimicrobial resistance (AMR), resulting in increased morbidity among tuberculosis cases. The Association of Southeast Asian Nations is home to approximately 10% of the world's population, account…
Christian Tague
HIV coinfection and multidrug-resistant tuberculosis (MDR-TB) pose a major public health challenge in sub-Saharan Africa, where high HIV prevalence promotes tuberculosis progression and complicates its management. In people living with HIV (PLHIV), profound immunosuppression lead…
Multidrug-Resistant Tuberculosis (MDR-TB) has become a major global health challenge because there is limited scope of treatment options when rifampicin and isoniazid -two frontline drugs in standard TB treatment regiments are resistant.This resistance significantly impairs the e…
Dragos Baiceanu, Laura Ioana Chivu, Roxana-Mihaela Coriu, Alexandru Stoichita, Traian-Constantin Panciu, et al.
**BACKGROUND/OBJECTIVES:** Multidrug-resistant tuberculosis (MDR-TB) remains a major public health challenge in the WHO European Region, which reports the highest global proportion of rifampicin-resistant and MDR-TB cases. Whole-genome sequencing (WGS) has emerged as a key tool f…
Aminu Shehu, Malik Olatunde Oduoye, Araj Naveed Siddiqui, Hareem Shaikh, Janice Odhiambo, et al.
Multidrug-resistant tuberculosis (MDR-TB) is an increasing public health issue that threatens the efforts in the treatment and control of tuberculosis (TB) worldwide, including in Nigeria. According to the World Health Organization, there were 558 000 MDR-TB cases globally in 201…
Ulan Kozhamkulov, Sholpan Iglikova, Anar Rakisheva, Joseph Almazan
: Multidrug-resistant tuberculosis (MDR-TB) remains a significant public health threat in Central Asia, where rising resistance to first-line anti-TB drugs challenges control efforts. As of 2024, the World Health Organization (WHO) reports that over 2.5% of new TB cases and 18% o…
Leeberk Raja Inbaraj, Bella Devaleenal Daniel, Chandrasekaran Padmapriyadarsini
…a. Simpler point of care diagnostic tests for Mycobacterium Tuberculosis detection and drug susceptibility testing, concentration of drugs used for DRTBM in CSF, optimal regimen and duration of treatment are some of the priority areas of research in DRTBM.
Gail B Cross
…W:** This review summarizes recent and emerging advances in tuberculosis (TB) treatment, focusing on new therapeutics, repurposed agents, and shortened treatment regimens. It aims to contextualize key developments within the evolving TB treatment landscape and assess their potent…
Radha Gopalaswamy, Selvakumar Subbian
SUMMARYThe global resurgence of drug-resistant tuberculosis (DR-TB) presents a formidable challenge to public health, driven by a complex interplay of mycobacterial evolution, dynamics and outcomes of host-pathogen interactions and systemic gaps in diagnosis and treatment strateg…
Leeberk Raja Inbaraj, Mukesh Kumar Sathya Narayanan, Priya Rajendran, Bella Devaleenal Daniel, Sivakumar Shanmugam, et al.
…s and treatment initiation are essential to prevent ongoing tuberculosis (TB) transmission and reduce the disease burden. Smear microscopy, which is widely used test for diagnosis, has limited sensitivity and does not detect rifampicin resistance. Truenat is a portable, battery-o…
Defne Yigci, İlker Kayı, Yusuf Ziya Demiroğlu, Murat Kutlu, Zeki Kılıçaslan, et al.
**BACKGROUND:** Tuberculosis (TB) remains a significant global public health challenge. We provide an overview of the current TB epidemiology in Turkey, highlighting key findings related to TB incidence, diagnostic challenges, and treatment outcomes. **RESULTS:** A gradual …
Radha Gopalaswamy, Bhargavi Subramanian, Manisha Parthasarathy, Chandrasekaran Padmapriyadarsini, Sivakumar Shanmugam
Timely detection of drug resistance is a pre-requisite to tuberculosis management globally. While phenotypic drug susceptibility testing (pDST) by liquid or solid method takes time, current genotypic DST assays can be performed directly from clinical specimens but target only a l…
Ashish Kumar Prakash, Chinkita Agrawal, Nishant Gupta, Pinky Goyal, Anand Jaiswal
…and minimizes the toxicity. In pulmonary and extrapulmonary tuberculosis (PTB/EPTB), it allows the physician to take actions timely for antitubercular treatment (ATT) regimen, required in patients who are responding slowly to the treatment. Early interventions may prevent drug re…
Edine Tiemersma, Susan van den Hof, Michael Kimerling
…ng available for the treatment of multidrug-resistant (MDR) tuberculosis (TB), the World Health Organization (WHO) recommended that countries should conduct active pharmacovigilance (PV) for these new drugs and regimens. Because of the complexity of MDR-TB treatment, which requir…
Ingrid Burkhardt, Florian Götzinger, Lahia Iipumbu, Elizabeth Whittaker, Gunar Günther, et al.
…en (<15 years) who develop multidrug-resistant (MDR) tuberculosis (TB) globally every year are diagnosed and started on appropriate treatment. However, recent years have brought rapid changes to diagnostics, prevention, and treatment strategies. **AREAS COVERED:** We pres…